Clinical Ink Competitors, Revenue, Alternatives and Pricing

Claim your profile


Winston-Salem, NC USA
Total Funding:$21.7M
Lead Investor(s):RTI International

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Clinical Ink's estimated annual revenue is currently $29.9M per year.
  • Clinical Ink received $Undisclosed in venture funding in May 2018.
  • Clinical Ink's estimated revenue per employee is $201,000
  • Clinical Ink's total funding is $21.7M.

Employee Data

  • Clinical Ink has 149 Employees.
  • Clinical Ink grew their employee count by 9% last year.
  • Clinical Ink currently has 9 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
BioDelivery Sci...
Quality Chemica...
LMK Clinical Re...
PMG Research
3D Communicatio...
WEP Clinical
Tanner Pharma G...
Nuventra Pharma...
Flow Sciences
Missing a competitor? Contribute!?

Clinical Ink is the leading provider of eSource solutions for the global clinical trials market. Founded in 2007, Clinical Ink® is transforming clinical development with innovative technologies that make clinical research easier for sites, sponsors and patients. Clinical Ink's SureSource® platform directly captures eSource data and documents and improves patient engagement while streamlining clinical development. Clinical Ink maintains offices in Winston-Salem, NC, and Philadelphia, PA. Find more at Our customer base includes pharmaceutical and medical device companies, academic institutions, and CROs. SureSource has been successfully used in a wide range of therapeutic areas including CNS, infectious diseases, dermatology, gastroenterology, and virology.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Clinical Ink News

09/03/2019 - Clinical Ink's Jonathan R. Andrus Receives 2019 Inspire ...

Winston-Salem, N.C.; May 14, 2019 (PR Newswire) – Clinical Ink, a global clinical trial technology company that is transforming the clinical trial ...

09/08/2019 - Lupin, Boehringer Ingelheim ink $700m licensing deal for anti-cancer drug

Lupin's MEK inhibitor compound completed initial Phase-I clinical trial in the UK. Now, Boehringer will take over the clinical development of the ...

09/03/2019 - CDC issues warning after outbreak of vaping-related illnesses

CDC, FDA, state and local health departments, and other clinical and public health partners are investigating a multistate outbreak of severe ...

Clinical Ink Funding

DateAmountRoundLead InvestorsReference
2013-10-17$4.3MBFCA Venture PartnersArticle
2015-03-19$UndisclosedUndisclosedMPM CapitalArticle
2018-05-15$UndisclosedUndisclosedRTI InternationalArticle

Clinical Ink Executive Hires

2016-03-11Stephen BoccardoChief Commercial OfficerArticle

Clinical Ink Acquisitions

DateCompany NameAmountNotesReference